NCT00376038CompletedPhase 1
A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 13
- Locations
- 2
- Primary Endpoint
- Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine
Study Overview
Brief Summary
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus (T2DM). Metformin is widely used in Europe and the USA for the treatment of T2DM. This study will evaluate the effect of GSK189075 on metformin levels in the blood in T2DM subjects. The rationale is to look for any safety problems that may result when the 2 drugs are given together.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 30 Years to 64 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have Type 2 diabetes mellitus.
- •Have a Body Mass Index within range 22 to 35kg/m2 inclusive.
- •Females who meet above criteria must be physiologically incapable of becoming pregnant (i.e., surgically sterilized, or post-menopausal per protocol definition).
Exclusion Criteria
- •Are currently taking insulin therapy.
- •Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or cancer).
- •Have a history of stomach, liver, kidney, or other disease that with interfere with taking the study drug.
- •Are currently using diuretics, oral or injectable corticosteroids (inhaled & intranasal corticosteroids are permitted), or other medications that would cause you to deplete your fluid balance in your body; currently taking stable regimens for heart conditions; currently using prescription or non-prescription drugs within 7 days of starting the study that may interfere with the study drug.
- •Would donate more than 450 ML of blood over a 2 month period.
- •Physician does not think it is a good idea for you to participate in the trial. - Had a urinary tract infection or bladder infection in the last month. - Are currently drinking more than 2 beers, 1 glass of wine, or 1 glass of spirits daily.
- •Have a positive urine drug screen test.
- •Plan to change your smoking habits during the course of the trial.
- •Have Hepatitis C, Hepatitis B, or HIV. - Have a lab or EKG abnormality. - High or low blood pressure.
- •Have used of any investigational drug or device during the study or within 30 days prior to 1st dosing of study medication.
- •Are a male subject unwilling to abstain or use protection during intercourse.
Outcomes
Primary Outcomes
Blood concentrations of metformin when given with GSK189075 in T2DM subjects over 3-day course Lab tests, changes in blood pressure and heart rate and heart activity on EKG machine
Secondary Outcomes
- Blood levels of drugs at Day 3 Evaluation of efficacy and safety markers on Days 1, 2, and 3.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Terminated
Phase 2
Effectiveness Of The Drug GSK189254 In Treating Patients With NarcolepsyNarcolepsyNCT00366080GlaxoSmithKline69
Completed
Phase 3
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary HyperhidrosisHyperhidrosisNCT01128738GlaxoSmithKline152
Completed
Phase 1
Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mgHealthy VolunteersNCT04316065Yuhan Corporation30
Completed
Phase 1
A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female VolunteersDiabetes Mellitus, Type 2Type 2 Diabetes MellitusNCT00504816GlaxoSmithKline22
Completed
Phase 1
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersType 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00501930GlaxoSmithKline12